- Home
- TORO vs ECOR Comparison
TORO vs ECOR Comparison
Compare TORO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- ECOR
- Stock Information
- Founded
- TORO 2022
- ECOR 2005
- Country
- TORO Cyprus
- ECOR United States
- Employees
- TORO N/A
- ECOR N/A
- Industry
- TORO Marine Transportation
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TORO Consumer Discretionary
- ECOR Health Care
- Exchange
- TORO Nasdaq
- ECOR Nasdaq
- Market Cap
- TORO 40.3M
- ECOR 40.1M
- IPO Year
- TORO N/A
- ECOR 2018
- Fundamental
- Price
- TORO $1.95
- ECOR $6.02
- Analyst Decision
- TORO
- ECOR Strong Buy
- Analyst Count
- TORO 0
- ECOR 2
- Target Price
- TORO N/A
- ECOR $25.50
- AVG Volume (30 Days)
- TORO 62.6K
- ECOR 130.4K
- Earning Date
- TORO 04-15-2025
- ECOR 05-07-2025
- Dividend Yield
- TORO N/A
- ECOR N/A
- EPS Growth
- TORO N/A
- ECOR N/A
- EPS
- TORO 1.09
- ECOR N/A
- Revenue
- TORO $22,394,283.00
- ECOR $25,182,000.00
- Revenue This Year
- TORO N/A
- ECOR $32.20
- Revenue Next Year
- TORO N/A
- ECOR $46.27
- P/E Ratio
- TORO $1.81
- ECOR N/A
- Revenue Growth
- TORO 0.40
- ECOR 57.09
- 52 Week Low
- TORO $1.70
- ECOR $5.02
- 52 Week High
- TORO $4.85
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- TORO 39.45
- ECOR 33.07
- Support Level
- TORO $1.70
- ECOR $5.20
- Resistance Level
- TORO $2.08
- ECOR $6.47
- Average True Range (ATR)
- TORO 0.24
- ECOR 0.71
- MACD
- TORO -0.01
- ECOR 0.33
- Stochastic Oscillator
- TORO 28.09
- ECOR 49.26
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.